Skip to main content
$0.200 0.005 (2.56%)

High

$0.21

Low

$0.19

Trades

113

Turnover

$359,726

Volume

1,808,064
30 June 2023 at 4:10pm
If you were already registered, log in here.

Short Interest

ASIC data, 1 Oct 2025

% Shorted

0.00% 0.02
vs 0.03% prior report

Most Shorted Rank

548th
of 717 shorted ASX stocks

Peak Short

1.12%
May 2020

Days to Cover

0.1
at 50d avg vol
Subject
IXC Ann: Phase III Clinical Trial Update and New IIH Market Analysis

IXC Ann: Invex Granted European Orphan Drug Designation for TBI

IXC Ann: Invex Receives Regulatory Approval for IIH EVOLVE in France

IXC Ann: Quarterly Activities/Appendix 4C Cash Flow Report

IXC Ann: Israel Ministry of Health Approval for IIH EVOLVE

IXC Ann: March Appendix 4C and Investor Conference Call Details

IXC Ann: Notification of cessation of securities - IXC

IXC Ann: German Approval for IIH EVOLVE Phase 3 Clinical Trial

IXC Ann: Publication of Invex IIH Phase II Pressure Trial Results

IXC Ann: Half Year Accounts

IXC Ann: Quarterly Activities/Appendix 4C Cash Flow Report

IXC Ann: Notification of cessation of securities - IXC

IXC Ann: Notice of Quarterly Investor Call

IXC Ann: First US Clinical Site Activated in IIH EVOLVE Phase III

IXC Ann: Invex Receives Approval for Paediatric Plan from the EMA

IXC Ann: Update - Notification regarding unquoted securities - IXC

IXC Ann: Change of Director's Interest Notice x 4

IXC Ann: Notification regarding unquoted securities - IXC

IXC Ann: Invex to Present at the MST Financial Biotech Forum

IXC Ann: MEDSAFE and Ethics Approval for IIH EVOLVE Trial in NZ

IXC Ann: Investor Presentation

IXC Ann: Results of Meeting

IXC Ann: AGM Presentation

IXC Ann: AGM Chairmans Address

IXC Ann: First Patient Randomised in IIH EVOLVE Phase III Trial

IXC Ann: Invex Receives $0.46 Million R&D Tax Rebate

IXC Ann: Quarterly Activities/Appendix 4C Cash Flow Report

IXC Ann: Upcoming Presentation at Argonaut Biotech Briefing

IXC Ann: September Appendix 4C and Investor Conference Call Details

IXC Ann: First UK Clinical Site Activated in IIH EVOLVE Phase 3 Trial

IXC Ann: First Australian Site Activated in IIH EVOLVE Phase 3

IXC Ann: Notice of Annual General Meeting/Proxy Form

IXC Ann: Second HREC Approval for IIH EVOLVE Phase III Clinical Trial

IXC Ann: Date of AGM and Director Nominations

IXC Ann: Invex to Present at Virtual ASX Small and Mid-Cap Conference

IXC Ann: Appendix 4G

IXC Ann: Corporate Governance Statement

IXC Ann: 4E and Annual Report to shareholders

IXC Ann: Invex receives IND approval

IXC Ann: Trading Halt

IXC Ann: Quarterly Activities/Appendix 4C Cash Flow Report

IXC Ann: HREC and TGA Approval to Commence Phase 3 in Australia

IXC Ann: Appendix 4C and Investor Conference Call Details

IXC Ann: Invex Receives UK Approval to Commence Phase III Trial

IXC Ann: Upcoming Presentations to the 15th EUNOS Meeting

IXC Ann: Invex to Present at Aerospace Medical Association Meeting

IXC Ann: Quarterly Activities/Appendix 4C Cash Flow Report

IXC Ann: March Appendix 4C and Investor Conference Call Details

IXC Ann: Executive Director Agreement

IXC Ann: Invex to Present at Upcoming Tech Biotech Broker Briefing

If you were already registered, log in here.

Similar Companies

CAN
CPH
EOF
IHL
MVP
MYX
NEU
PBP
RCE
SPL
S88
MAV
CX8
MTX $12m raise
ATW $7.5m raise
RDO $30m raise
ABC $5m raise
RGS